GE HealthCare, Siemens Healthineers and Philips are working on generative AI products that aggregate patient data to make ...

The global intravascular imaging market is poised for significant expansion, with its valuation expected to rise from USD 387.8 million in 2023 to USD 656.29 million by 2033. This substantial growth, ...

The purchase of the shares of Siemens Healthineers AG is carried out by a credit institution that has been commissioned by Siemens Healthineers AG; the shares are repurchased exclusively on the ...

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

Siemens and Accenture have launched the Accenture Siemens Business Group at Hannover Messe 2025, a major new initiative that brings together over ...

The firm's Innovance Antithrombin assay is used to monitor antithrombin activity levels in hemophilia patients and aid dosing decisions for a routine prophylaxis.

The antithrombin assay will support dosing Qfitlia, the sixth Alnylam-discovered RNAi medicine to receive FDA approval.

FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...

Siemens Healthineers is advancing AI and robotics in healthcare to improve patient outcomes, enhance automation, and reduce ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Siemens Healthineers AG (SEMHF – Research ...

Siemens and Accenture (NYSE: ACN) are significantly advancing their long-standing alliance partnership to help clients reinvent and transform engineering and manufacturing. This press release features ...